Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.

Article  CAS  PubMed  Google Scholar 

Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53(5):1793–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–60.

Article  PubMed  PubMed Central  Google Scholar 

Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T, Fourth European Conference on Infections in Leukaemia; Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EBMT-IDWP); Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG). ; International Immunocompromised Host Society (ICHS); European Leukaemia Net (ELN). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014; 15(8):e327-40.

Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother. 2014;69(6):1633–41.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Adams AD, Benner RS, Riggs TW, Chescheir NC. Use of the STROBE Checklist to evaluate the Reporting Quality of Observational Research in Obstetrics. Obstet Gynecol. 2018;132(2):507–12.

Article  PubMed  Google Scholar 

Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, Koo HH, Kim YJ. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013;60(1):82–7.

Article  CAS  PubMed  Google Scholar 

Kato K, Nagao M, Yamamoto M, Matsumura Y, Takakura S, Fukuda K, Ichiyama S. Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients. J Infect Chemother. 2016;22(1):27–31.

Article  CAS  PubMed  Google Scholar 

Liu L, Zhou X, Wu T, Jiang H, Yang S, Zhang Y. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China. Int J Antimicrob Agents. 2017;49(4):483–7.

Article  CAS  PubMed  Google Scholar 

Hu L, Dai T-T, Zou L, Li T-M, Ding X-S, Yin T. Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother. 2018;62:e00955–18.

Article  PubMed  PubMed Central  Google Scholar 

Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X. Impact of CYP2C19 phenotype and drug-drug interactions on Voriconazole Concentration in Pediatric patients. Antimicrob Agents Chemother. 2021;65(9):e0020721.

Article  PubMed  Google Scholar 

Chen J, Wu Y, He Y, Feng X, Ren Y, Liu S. Combined effect of CYP2C19 genetic polymorphisms and C-Reactive protein on Voriconazole exposure and dosing in Immunocompromised Children. Front Pediatr. 2022;10:846411.

Article  PubMed  PubMed Central  Google Scholar 

Hu L, Huang Q, Huang S, Feng Z. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients. Eur J Clin Pharmacol. 2023;79(9):1271–8.

Article  CAS  PubMed  Google Scholar 

Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, Lortholary O, Jullien V. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monit. 2011;33(4):464–6.

Article  CAS  PubMed  Google Scholar 

Soler-Palacín P, Frick MA, Martín-Nalda A, Lanaspa M, Pou L, Roselló E, de Heredia CD, Figueras C. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother. 2012;67(3):700–6.

Article  PubMed  Google Scholar 

Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 2012;67(11):2717–24.

Article  CAS  PubMed  Google Scholar 

Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, Boelens JJ, Bierings M. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57(1):235–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, Peloquin CA. Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther. 2015;20(1):17–23.

PubMed  PubMed Central  Google Scholar 

Boast A, Curtis N, Cranswick N, Gwee A. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother. 2016;71(7):2031–6.

Article  CAS  PubMed  Google Scholar 

Zembles TN, Dasgupta M, Kenkel TJ, Lehrer B, Simpson P, Havens PL, Huppler AR. Higher weight-based doses are required to Achieve and maintain therapeutic voriconazole serum trough concentrations in children. J Pediatr Pharmacol Ther. 2023;28(3):247–54.

PubMed  PubMed Central  Google Scholar 

Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicolò A, Cusato J, Di Perri G, D’Avolio A. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Br J Clin Pharmacol. 2018;84(1):197–203.

Article  CAS  PubMed  Google Scholar 

Allegra S, Fatiguso G, Francia S, Pirro E, Carcieri C, Cusato J, Nicolò A, Avataneo V, Perri GD, D’Avolio A. Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics. 2018;19(11):913–25.

Article  CAS  PubMed  Google Scholar 

Espinoza N, Galdames J, Navea D, Farfán MJ, Salas C. Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children. Sci Rep. 2019;9(1):8863.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang S, Yee J, Kim JY, Han HW, Kang SO, Lee KE, Gwak HS. Factors Associated with Voriconazole Concentration in Pediatric patients. Ther Drug Monit. 2020;42(6):866–71.

Article  CAS  PubMed  Google Scholar 

Zhao YC, Zou Y, Hou JJ, Xiao CL, Zhang BK, Li JK, Xiang DX, Sandaradura I, Yan M. Factors affecting voriconazole trough concentration and optimal maintenance voriconazole dose in Chinese children. Antibiot (Basel). 2021;10(12):1542.

Article  CAS  Google Scholar 

Valle-T-Figueras JM, Renedo Miró B, Benítez Carabante MI, Díaz-de-Heredia C, Vima Bofarull J, Mendoza-Palomar N, Martín-Gómez MT. Soler-Palacín P. Voriconazole Use in Children: therapeutic drug monitoring and Control of Inflammation as key points for optimal treatment. J Fungi (Basel). 2021;7(6):456.

Article  CAS  PubMed  Google Scholar 

Luo X, Li T, Hu L, Liu S, Zhao H, Zhang J, Feng Y, Huang L. Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients. J Chemother. 2021;33(2):95–105.

Article  CAS  PubMed  Google Scholar 

Chen X, Xiao Y, Li H, Huang Z, Gao J, Zhang X, Li Y, Van Timothee BM, Feng X. Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children. Transl Pediatr. 2022;11(8):1311–22.

Article  PubMed  PubMed Central  Google Scholar 

Tilen R, Paioni P, Goetschi AN, Goers R, Seibert I, Müller D, Bielicki JA, Berger C, Krämer SD. Meyer Zu Schwabediss